177 related articles for article (PubMed ID: 29992026)
1. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
2. Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics.
Saiz-Rodríguez M; Ochoa D; Román M; Zubiaur P; Koller D; Mejía G; Abad-Santos F
Pharmacogenomics; 2020 Jul; 21(10):663-675. PubMed ID: 32538291
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
6. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
[TBL] [Abstract][Full Text] [Related]
7. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.
Casajús A; Zubiaur P; Alday E; Soria-Chacartegui P; Saiz-Rodríguez M; Gutierrez L; Aragonés C; Campodónico D; Gómez-Fernández A; Navares-Gómez M; Villapalos-García G; Mejía-Abril G; Ochoa D; Abad-Santos F
Clin Transl Sci; 2024 Jan; 17(1):e13698. PubMed ID: 38140786
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
14. Rifampicin markedly decreases the exposure to oral and intravenous tramadol.
Saarikoski T; Saari TI; Hagelberg NM; Neuvonen M; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
Eur J Clin Pharmacol; 2013 Jun; 69(6):1293-301. PubMed ID: 23242004
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of the enantiomers of tramadol and its three main metabolites in human whole blood using LC-MS/MS.
Haage P; Kronstrand R; Carlsson B; Kugelberg FC; Josefsson M
J Pharm Biomed Anal; 2016 Feb; 119():1-9. PubMed ID: 26625281
[TBL] [Abstract][Full Text] [Related]
16. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
[TBL] [Abstract][Full Text] [Related]
17. Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics.
de Moraes NV; Lauretti GR; Napolitano MN; Santos NR; Godoy AL; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 880(1):140-7. PubMed ID: 22173007
[TBL] [Abstract][Full Text] [Related]
18. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol.
Tzvetkov MV; Saadatmand AR; Lötsch J; Tegeder I; Stingl JC; Brockmöller J
Clin Pharmacol Ther; 2011 Jul; 90(1):143-50. PubMed ID: 21562485
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681776
[TBL] [Abstract][Full Text] [Related]
20. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
